SCHEMBL7901973

SCHEMBL7901973

CCc1ccc2c(c1)NS(=O)(=O)NC2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.38
SLC40A1 Q9NP59 1/20 0.35
TRPA1 O75762 1/20 0.32
DRD2 P14416 1/20 0.32
DRD1 P21728 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2A6 P11509 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7901542 0.87 PARP1 (0.35) PARP1SLC40A1TRPA1HTR2AHTR2C
SCHEMBL12846433 0.78 SLC40A1 (0.38) PARP1SLC40A1ALDH1A1MAPTCYP1A2
SCHEMBL10060228 0.77 PARP1 (0.40) PARP1TRPA1HTR2AHTR2CHTR2B
SCHEMBL7902885 0.75 PARP1 (0.44) PARP1TRPA1NPC1RAB9ASMN1; SMN2
SCHEMBL3600562 0.75 CA9 (0.42) SLC40A1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL31487844 0.75 SLC40A1 (0.38) SLC40A1DRD2DRD1
SCHEMBL15457664 0.74 HPGD (0.37) SLC40A1TRPA1ALDH1A1LMNA
SCHEMBL10060227 0.72 SRD5A1 (0.34) PARP1TRPA1DRD2DRD1HTR2A
SCHEMBL7904921 0.72 PARP1 (0.33) PARP1TRPA1DRD2DRD1HTR2A
SCHEMBL18087326 0.70 GRIA2 (0.42) PARP1TRPA1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 PARP1 4016/4885SLC40A1 1710/4885TRPA1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.